Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration

About this resource:

Systematic Review

Source: The Cochrane Collaborative

Last Reviewed: March 2019

Workgroups: Vision Workgroup

In this Cochrane systematic review, the Cochrane Collaborative found that anti‐vascular endothelial growth factor (anti‐VEGF) medicines — pegaptanib, ranibizumab and bevacizumab — improve vision and reduce vision loss in people with neovascular age‐related macular degeneration (wet AMD). People treated with anti-VEGF medicines also had improvements in eye structure. In addition, researchers found that participants who took ranibizumab or bevacizumab for at least 1 year had similar vision outcomes. The main difference between treatments was cost (bevacizumab was cheaper), and very few serious side effects occurred. 

Read more about this resource

Objectives related to this resource (1)

Suggested Citation


Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2014). Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews, 2014 (8). DOI: 10.1002/14651858.CD005139.pub4.